signaling threshold regulating transmembrane adaptor 1Genealiases: SIT · SIT-R
Q-omics provides the consensus-scored SIT1 profile across patient tissues and cancer cell-line models. SIT1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SIT1 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, SIT1 RNA expression shows 20,106 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where SIT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SIT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SIT1 survival associations across molecular data types. SIT1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SIT1 RNA expression–survival associations across cancer types. High SIT1 expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, UCEC, SCLC and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SIT1 RNA expression.
This table summarizes SIT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SIT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SIT1 shows lower tumor expression in LUSC, THCA and COAD and higher tumor expression in KIRC, LIHC and KIRP. The KIRC box plot shows higher SIT1 RNA expression in tumor versus normal tissue (log2 FC = +2.228, t-test p < 0.001).
This table shows molecular features associated with SIT1 in patient tissues and cancer cell lines. In patient samples, SIT1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SIT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
